The Distribution Partnering
Terms and Agreements report provides comprehensive understanding and
unprecedented access to the distribution partnering agreements entered into by
the worlds leading biopharma companies.
Description
The Distribution Partnering Terms
and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive
understanding and unprecedented access to the distribution partnering
agreements entered into by the worlds leading biopharma companies.
The report provides a detailed
understand and analysis of how and why companies enter distribution deals.
The majority of deals are
multicomponent whereby the licensor offers a right to distribute the resultant
product of the research collaboration. There are also numerous pure
distribution deals whereby the products originator takes on a distribution
partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a
prospective partner’s negotiated deals terms provides critical insight into the
negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of
the payments clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases and databases
do not.
The initial chapters of this
report provide an orientation of distribution dealmaking and business
activities. Chapter 1 provides an introduction to the report, whilst chapter 2
provides an analysis of the trends in distribution as well as a discussion on
the merits of the type of deal.
Chapter 3 provides an overview of
the structure of distribution deals. The chapter includes numerous case studies
to enable understanding of both pure distribution deals and multicomponent
deals where distribution forms a part.
Chapter 4 provides a review of the
leading distribution deals since 2009. Deals are listed by headline value,
signed by big pharma and big biotech, most active bigpharma and bigbiotech, and
most active of all biopharma companies. Where the deal has an agreement
contract published at the SEC a link provides online access to the contract via
the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive
listing of the top 50 big pharma companies with a brief summary followed by a
comprehensive listing of distribution deals available in the public domain.
Where available, each deal title links via Current Agreements deals and
alliances database to an online version of the actual contract document,
providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive
listing of the top 50 big biotech companies with a brief summary followed by a
comprehensive listing of distribution deals available in the public domain.
Where available, each deal title links via Current Agreements deals and
alliances database to an online version of the actual contract document, providing
easy access to each contract document on demand.
Chapter 7 provides a comprehensive
and detailed review of distribution deals organized by company A-Z, therapy,
technology and industry type signed and announced since 2009 where a contract
document is available. Contract documents provide an indepth insight into the
actual deal terms agreed between the parties with respect to the distribution
deal.
In addition the report includes a
comprehensive listing of all distribution deals announced since 2009.
Each listing is organized as an
appendix by company A-Z, stage of development at signing, therapeutic area and
industry type. Each deal title links via hyperlink to an online version of the
deal record including, where available, the actual contract document.
The report also includes numerous
table and figures that illustrate the trends and activities in distribution
dealmaking since 2009.
In conclusion, this report
provides everything a prospective dealmaker needs to know about distribution alliances.
Report scope
Distribution Partnering Terms and
Agreements is intended to provide the reader with an in-depth understanding of
the distribution trends and structure of deals entered into by leading
biopharma companies worldwide.
Distribution Partnering Terms
and Agreements includes:
- Trends in distribution
dealmaking in the biopharma industry since 2009
- Analysis of distribution deal
structure
- Case studies of real-life
distribution deals
- Access to over 2,500
distribution deals documents
- The leading distribution deals
by value since 2009
- Most active distribution
dealmakers since 2009
- The leading distribution
partnering resources
In Distribution Partnering
Terms and Agreements, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Therapeutic area
- Technology type
Each deal title links via Weblink
to an online version of the actual deal record, providing easy access to each
contract document where available.
The Distribution Partnering Terms
and Agreements report provides comprehensive access to available records for
over 2,500 distribution deals, including contract documents where available.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Distribution Partnering Terms
and Agreements in Pharma, Biotech and Diagnostics report provides the reader
with the following key benefits:
- In-depth understanding of distribution deal trends since 2009
- Analysis of the structure of distribution with numerous real life case studies
- Comprehensive access to over 2,000 distribution deals entered into by the world’s biopharma companies, together with contract documents if available
- Detailed access to actual distribution contracts entered into by the leading fifty big pharma and big biotech companies
- Identify leading distribution deals by value since 2009
- Identify the most active distribution dealmakers since 2009
- Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
- Full listing of distribution deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 2477 pages and 12 Figures “Distribution Partnering Terms and
Agreements in Pharma, Biotech and Diagnostics” report Covering Executive
Summary, Introduction, Trends in distribution dealmaking, Overview of
distribution deal structure, Leading distribution deals, Big pharma
distribution deals, Big biotech distribution deals, Distribution deals
including contracts directory, Appendix.
Know more
about this report at – http://mrr.cm/45V
Find all Healthcare Reports
at: http://www.marketresearchreports.com/healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.